Gynecologic Cancer
EC145 in Combination With Doxil® for Platinum Resistant Ovarian Cancer (7334)
Protocol EC-FV-06: A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (Pld/Doxil®/Caelyx®) In Combination Versus PLD In Participants with Platinum-Resistant Ovarian Cancer
Investigator: Barbara Ann Goff, MD; Conditions: Ovarian Cancer; Status: Recruiting; Study ID: NCT01170650
A Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy-Naïve Patients with Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus or Ovary
Investigator: Benjamin Greer, MD; Conditions: Gynecological Cancer; Ovarian Cancer; Solid Tumors; Uterine Cancer; Status: Recruiting; Study ID: NCT00954174
A Phase I Trial of the Safety and Immunogenicity of a DNA Plasmid Based Vaccine Encoding the Amino Acids 1-163 of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in Patients With Advanced Ovarian Cancer
Investigator: Mary L. Disis, MD; Conditions: Ovarian Cancer; Status: Recruiting; Study ID: NCT01322802
A Randomized Phase III Trialof Cisplatin and Tumor Volume Directional Irradiation Followed By Carboplatin and Paclitaxel Vs.for Optimally Debulked, Advanced Endometrial Carcinoma
Investigator: Benjamin Greer, MD; Conditions: Endometrial Cancer; Status: Recruiting; Study ID: NCT00942357
A Phase III Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed By Paclitaxel/Carboplatin Chemotherapy in Patients With High Risk, Early Stage Endometrial Carcinoma
Investigator: Benjamin E. Greer, MD; Conditions: Endometrial Cancer, Fatigue, Neurotoxicity; Status: Recruiting; Study ID: NCT00807768
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel Alone or in Combination With Bevacizumab (NSC #704865, IND #7921) Followed by Bevacizumab and Secondary Cytoreduction Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer
Investigator: Benjamin E. Greer, MD; Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer; Status: Recruiting; Study ID: NCT00565851
A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax (CT-2103) (IND# 70177), Versus No Treatment Until Documented Relapse in Women With Advanced Ovarian or Primary Peritoneal or Fallopian Tube Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
Investigator: Benjamin E. Greer, MD; Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer; Status: Recruiting; Study ID: NCT00108745
A Phase 1, Open-label, Dose-escalation, Multidose Study of MDX-1105 Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors
Investigator: Scott S. Tykodi, MD, PhD; Conditions: Renal Cell Carcinoma, Non-small Cell Lung Cancer, Malignant Melanoma, Epithelial Ovarian Cancer; Status: Recruiting; Study ID: NCT00729664
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients With Ovarian or Breast Cancer
Investigator: Barbara A. Goff, MD; Conditions: Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Cancer, Breast Carcinoma; Status: Closed; Study ID: NCT01091428
A Phase 1 Study of ABT-888 (Veliparib) in Combination With Carboplatin (Paraplatin) and Gemcitabline (Gemzar) in Subjects With Advanced Solid Tumors
Investigator: Heidi J. Gray, MD; Conditions: Advanced Solid Tumors; Status: Closed; Study ID: NCT01063816
A Randomized Phase II Evaluation of Weekly Paclitaxel (NSC #673089) Plus Pazopanib (NSC #737754) (IND #75648) Versus Weekly Paclitaxel Plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma
Investigator: Benjamin Greer, MD; Conditions: Ovarian Epithelial Cancer, Fallopian Tube Cancer, Peritoneal Cavity Cancer; Status: Recruiting; Study ID: NCT01468909
A Phase II Evaluation of Cediranib (Recentin; AZD2171, IND# 72740, NSC# 732208) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Investigator: Benjamin Greer, MD; Conditions: Endometrial Cancer; Status: Recruiting; Study ID: NCT01132820
A Phase II Evaluation of BIBF 1120 (IND #) in the Treatment of Recurrent or Persistent Endometrial Carcinoma
Investigator: Benjamin Greer, MD; Conditions: Endometrial Cancer; Status: On Hold; Study ID: NCT01225887
EP-100, a Novel LHRH Receptor-Targeted Membrane-Disruptive Peptide, plus Paclitaxel® versus Paclitaxel® alone for Refractory or Recurrent Ovarian Cancer: a Phase II, Randomized, Multi-Center Trial
Investigator: Renata R. Urban, MD; Conditions: Ovarian Cancer Recurrent; Status: Recruiting; Study ID: NCT01485848
Behavioral and Neural Indices of Cognitive Rehabilitation in Ovarian Cancer: A Pilot Study
Investigator: Heidi J. Gray, MD; Conditions: Ovarian Cancer; Status: Recruiting; Study ID: NCT01641068
A Phase II Evaluation of Dalantercept, A Novel Soluable Recombinant Activin Receptor-Like Kinase 1 (ALK-1) Inhibitor Receptor-Fusion Protein, in Treatment of Recurrent or Persistent Endometrial Carcinoma
Investigator: Benjamin Greer, MD; Conditions: Endometrial Cancer; Status: Recruiting; Study ID: NCT01642082
Randomized Phase 2 Study of MLN8237, an Aurora A Kinase Inhibitor, Plus Weekly Paclitaxel or Weekly Paclitaxel Alone in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, Preceded by a Phase 1 Portion in Patients with Ovarian or Breast Cancer
Investigator: Barbara Ann Goff, MD; Conditions: Ovarian Cancer, Breast Cancer, Fallopian Cancer, Peritoneal Cancer; Status: Recruiting; Study ID: NCT01091428
Join Us On